In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Intarcia secures $225mm via royalty financing; adds $75mm; $100mm milestone paid

Executive Summary

Intarcia Therapeutics Inc. secured $225mm in exchange for 1.5% of future worldwide net sales of its ITCA650, which is currently in Phase III as a once or twice yearly subcutaneous exenatide for Type II diabetes. Morgan Stanley was the structuring agent.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register